AHSCT may help reactivate the thymus in some MS patients, which could support the immune system.
Researchers looked at 15 MS patients who had a special treatment called AHSCT. They found that 3 out of these 15 patients showed signs of thymic hyperplasia, which is when the thymus gland gets bigger and can help make new immune cells. This change happened 1 to 3 months after the treatment. All patients were healthy without new MS symptoms or treatments for an average of 36 months after AHSCT. The study suggests that AHSCT might help the thymus work better, which is important for fighting off illnesses.
MS patients should care because this study shows that a treatment they may receive could help support their immune system. If the thymus is working better, it could mean fewer infections and better overall health. Caregivers can also benefit from understanding how AHSCT might improve their loved ones' immune function. This knowledge could help them feel more hopeful about treatment options. Overall, anyone involved in MS care should pay attention to these findings as they could impact daily life and health management.
This study included a small number of patients, which means the findings may not apply to everyone with MS. The researchers didn’t find a strong link between thymic hyperplasia and the health outcomes of the patients. It’s also important to remember that while some patients showed changes, others did not, so more research is needed to understand the full impact.
12/31/2026
Learn how certain gut bacteria can worsen MS symptoms and what this means for treatment and daily li
Read More5/1/2026
Study finds CD29 marks blood B cells that can enter the brain and become antibody-producing cells in
Read More5/1/2026
Study finds early detection, lower spinal fluid virus, and PML‑IRIS relate to better 1‑year outcomes
Read More5/1/2026
Study found fewer hospital diagnoses of antibody-positive autoimmune encephalitis during COVID-19, b
Read More3/1/2026
Study shows C5 inhibitors given during or soon after NMOSD attacks helped most patients stabilize or
Read More3/1/2026
Early OCT eye scans can often distinguish MOGAD from NMOSD optic neuritis, helping guide faster trea
Read MoreWhether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Frontiers in immunology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.
However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.
By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.